Baird Maintains Bullish View on Karyopharm Therapeutics (KPTI) Following Positive STORM Results
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Baird analyst Michael Ulz reiterated an Outperform rating and $16 price target on Karyopharm Therapeutics (NASDAQ: KPTI) following Phase 2b STORM data, which was positive as expected.
Ulz commented, "Selinexor achieved an overall response rate (ORR) of 20% in penta-refractory multiple myeloma (MM), meeting the bar to expand the study, which had been announced last week. Importantly, the expanded STORM study will support accelerated approval, while the Phase 3 BOSTON study, announced today, will support full approval and enable selinexor to move upstream in the treatment paradigm. Overall, with encouraging STORM data, continued advancement in MM and multiple catalysts ahead, we reiterate our Outperform rating."
Shares of Karyopharm Therapeutics closed at $10.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roth Capital Trims PT on Aduro Biotech (ADRO) to $20 Amid FDA Partial Hold on LADD Trials
- Jefferies Reiterates Buy on PPG Industries (PPG) - PT to $113
- UPDATE: Stifel Downgrades SL Green Realty (SLG) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!